Oncomed Pharmaceuticals Inc (OMED) Given Average Recommendation of “Hold” by Brokerages
Shares of Oncomed Pharmaceuticals Inc (NASDAQ:OMED) have been assigned a consensus rating of “Hold” from the ten research firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and two have issued a buy rating on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $6.33.
A number of analysts have weighed in on the company. Cantor Fitzgerald restated a “hold” rating and issued a $6.00 price target on shares of Oncomed Pharmaceuticals in a research note on Tuesday, September 19th. Jefferies Group LLC set a $5.00 price target on Oncomed Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, August 25th. Finally, Piper Jaffray Companies set a $5.00 price target on Oncomed Pharmaceuticals and gave the company a “hold” rating in a research note on Monday, July 10th.
COPYRIGHT VIOLATION NOTICE: This report was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://www.watchlistnews.com/oncomed-pharmaceuticals-inc-omed-given-average-recommendation-of-hold-by-brokerages/1600465.html.
Shares of Oncomed Pharmaceuticals (NASDAQ:OMED) opened at 4.52 on Friday. The firm’s 50-day moving average price is $4.27 and its 200 day moving average price is $4.85. The stock’s market cap is $170.09 million. Oncomed Pharmaceuticals has a 1-year low of $2.91 and a 1-year high of $12.56.
Oncomed Pharmaceuticals (NASDAQ:OMED) last posted its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.50) by $0.10. The business had revenue of $6.20 million during the quarter, compared to analyst estimates of $6.08 million. During the same quarter in the prior year, the business earned ($0.91) earnings per share. The firm’s quarterly revenue was down 7.0% on a year-over-year basis. On average, equities analysts expect that Oncomed Pharmaceuticals will post ($1.85) earnings per share for the current fiscal year.
Hedge funds have recently modified their holdings of the business. American International Group Inc. grew its holdings in shares of Oncomed Pharmaceuticals by 9.0% during the first quarter. American International Group Inc. now owns 10,977 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 905 shares during the last quarter. KCG Holdings Inc. purchased a new position in shares of Oncomed Pharmaceuticals during the first quarter worth about $103,000. Russell Investments Group Ltd. purchased a new position in shares of Oncomed Pharmaceuticals during the first quarter worth about $141,000. Metropolitan Life Insurance Co. NY purchased a new position in shares of Oncomed Pharmaceuticals during the first quarter worth about $160,000. Finally, Teachers Advisors LLC grew its holdings in shares of Oncomed Pharmaceuticals by 10.8% during the fourth quarter. Teachers Advisors LLC now owns 30,423 shares of the biopharmaceutical company’s stock worth $235,000 after purchasing an additional 2,961 shares during the last quarter. 51.72% of the stock is currently owned by institutional investors.
Oncomed Pharmaceuticals Company Profile
OncoMed Pharmaceuticals, Inc (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. The Company’s therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11).
Receive News & Ratings for Oncomed Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncomed Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.